Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Gains from Investment Securities: 2015-2025

Historic Gains from Investment Securities for Cartesian Therapeutics (RNAC) over the last 7 years, with Sep 2025 value amounting to -$516,000.

  • Cartesian Therapeutics' Gains from Investment Securities rose 90.90% to -$516,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year increase of 71.13%. This contributed to the annual value of -$2.6 million for FY2024, which is 79.93% up from last year.
  • As of Q3 2025, Cartesian Therapeutics' Gains from Investment Securities stood at -$516,000, which was up 21.10% from -$654,000 recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year Gains from Investment Securities high stood at $16.7 million for Q1 2021, and its period low was -$18.5 million during Q1 2022.
  • Over the past 3 years, Cartesian Therapeutics' median Gains from Investment Securities value was -$1.0 million (recorded in 2024), while the average stood at -$1.7 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Gains from Investment Securities spiked by 1,879.55% in 2021 and then slumped by 236.45% in 2023.
  • Over the past 5 years, Cartesian Therapeutics' Gains from Investment Securities (Quarterly) stood at -$9.0 million in 2021, then plummeted by 50.66% to -$13.6 million in 2022, then spiked by 50.59% to -$6.7 million in 2023, then soared by 103.66% to $245,000 in 2024, then skyrocketed by 90.90% to -$516,000 in 2025.
  • Its Gains from Investment Securities was -$516,000 in Q3 2025, compared to -$654,000 in Q2 2025 and -$1.8 million in Q1 2025.